Join to view full profile
4525 Cameron Valley PkwySuite 3500Charlotte, NC 28211
Phone+1 704-302-8300
Fax+1 704-302-8301
Dr. Nazemzadeh is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006- Vanderbilt University Medical CenterResidency, Internal Medicine, 2000 - 2003
McGovern Medical School at UTHealthClass of 2000
Certifications & Licensure
NC State Medical License 2006 - 2027
TN State Medical License 2003 - 2006
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2013-2014, 2017
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2013-2014, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Healthe, Cerner Patient Portal, HealthSentry and P2 Sentinel, Cerner Corporation, 2013-2014, 2017
Clinical Trials
- S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride Start of enrollment: 2011 Nov 15
- A Study of Regorafenib in Advanced Pancreatic Cancer Patients Start of enrollment: 2014 Jun 06
Publications & Presentations
PubMed
- Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.Paula M Novelli, Emmanuel E Zervos, Amer H Zureikat, Michael J Pishvaian, Kenneth Meredith
Cancer Chemotherapy and Pharmacology. 2026-08-17 - 36 citationsCobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, Pam K Mangat, Reza Nazemzadeh
JCO Precision Oncology. 2022-11-01 - 11 citationsErratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreat...Bert H. O'Neil, Aaron Scott, W. W. Ma, Steven J. Cohen, Dara L. Aisner
Annals of Oncology. 2016-06-18
Press Mentions
Gut Health Is Important for All AgesFebruary 24th, 2023- ‘A Watershed Moment': A Pancreatic Cancer Drug Is Set to Transform TreatmentMay 7th, 2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: